Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 106

1.

Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome.

Carmona-Iragui M, Santos T, Videla S, Fernández S, Benejam B, Videla L, Alcolea D, Blennow K, Blesa R, Lleó A, Fortea J.

J Alzheimers Dis. 2016 Nov 14. [Epub ahead of print]

PMID:
27858714
2.

Kidins220 Correlates with Tau in Alzheimer's Disease Brain and Cerebrospinal Fluid.

Gamir-Morralla A, Belbin O, Fortea J, Alcolea D, Ferrer I, Lleó A, Iglesias T.

J Alzheimers Dis. 2016 Nov 14. [Epub ahead of print]

PMID:
27858709
3.

Longitudinal brain structural changes in preclinical Alzheimer's disease.

Pegueroles J, Vilaplana E, Montal V, Sampedro F, Alcolea D, Carmona-Iragui M, Clarimon J, Blesa R, Lleó A, Fortea J; Alzheimer's Disease Neuroimaging Initiative..

Alzheimers Dement. 2016 Sep 28. pii: S1552-5260(16)32890-4. doi: 10.1016/j.jalz.2016.08.010. [Epub ahead of print]

PMID:
27693189
4.

Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome.

Hamlett ED, Goetzl EJ, Ledreux A, Vasilevko V, Boger HA, LaRosa A, Clark D, Carroll SL, Carmona-Iragui M, Fortea J, Mufson EJ, Sabbagh M, Mohammed AH, Hartley D, Doran E, Lott IT, Granholm AC.

Alzheimers Dement. 2016 Oct 15. pii: S1552-5260(16)32892-8. doi: 10.1016/j.jalz.2016.08.012. [Epub ahead of print]

PMID:
27755974
5.

CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study.

Dangla-Valls A, Molinuevo JL, Altirriba J, Sánchez-Valle R, Alcolea D, Fortea J, Rami L, Balasa M, Muñoz-García C, Ezquerra M, Fernández-Santiago R, Lleó A, Lladó A, Antonell A.

Mol Neurobiol. 2016 Oct 13. [Epub ahead of print]

PMID:
27738874
6.

Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimer's disease.

Sogorb-Esteve A, García-Ayllón MS, Fortea J, Sánchez-Valle R, Lleó A, Molinuevo JL, Sáez-Valero J.

Mol Neurodegener. 2016 Sep 29;11(1):66.

7.

Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer's Disease: Potential and Limitations.

Cosín-Tomás M, Antonell A, Lladó A, Alcolea D, Fortea J, Ezquerra M, Lleó A, Martí MJ, Pallàs M, Sanchez-Valle R, Molinuevo JL, Sanfeliu C, Kaliman P.

Mol Neurobiol. 2016 Sep 8. [Epub ahead of print]

PMID:
27631879
8.

Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid Aβ42 Levels in Cognitively Normal Elderly.

Varga AW, Wohlleber ME, Giménez S, Romero S, Alonso JF, Ducca EL, Kam K, Lewis C, Tanzi EB, Tweardy S, Kishi A, Parekh A, Fischer E, Gumb T, Alcolea D, Fortea J, Lleó A, Blennow K, Zetterberg H, Mosconi L, Glodzik L, Pirraglia E, Burschtin OE, de Leon MJ, Rapoport DM, Lu SE, Ayappa I, Osorio RS.

Sleep. 2016 Nov 1;39(11):2041-2048.

PMID:
27568802
9.

Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study.

Leuzy A, Chiotis K, Hasselbalch SG, Rinne JO, de Mendonça A, Otto M, Lleó A, Castelo-Branco M, Santana I, Johansson J, Anderl-Straub S, von Arnim CA, Beer A, Blesa R, Fortea J, Herukka SK, Portelius E, Pannee J, Zetterberg H, Blennow K, Nordberg A.

Brain. 2016 Sep;139(Pt 9):2540-53. doi: 10.1093/brain/aww160.

10.

A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer's disease.

Verheijen J, Van den Bossche T, van der Zee J, Engelborghs S, Sanchez-Valle R, Lladó A, Graff C, Thonberg H, Pastor P, Ortega-Cubero S, Pastor MA, Benussi L, Ghidoni R, Binetti G, Clarimon J, Lleó A, Fortea J, de Mendonça A, Martins M, Grau-Rivera O, Gelpi E, Bettens K, Mateiu L, Dillen L, Cras P, De Deyn PP, Van Broeckhoven C, Sleegers K.

Acta Neuropathol. 2016 Aug;132(2):213-24. doi: 10.1007/s00401-016-1566-9.

11.

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.

Suárez-Calvet M, Kleinberger G, Araque Caballero MÁ, Brendel M, Rominger A, Alcolea D, Fortea J, Lleó A, Blesa R, Gispert JD, Sánchez-Valle R, Antonell A, Rami L, Molinuevo JL, Brosseron F, Traschütz A, Heneka MT, Struyfs H, Engelborghs S, Sleegers K, Van Broeckhoven C, Zetterberg H, Nellgård B, Blennow K, Crispin A, Ewers M, Haass C.

EMBO Mol Med. 2016 May 2;8(5):466-76. doi: 10.15252/emmm.201506123.

12.

White Matter Abnormalities Track Disease Progression in PSEN1 Autosomal Dominant Alzheimer's Disease.

Sánchez-Valle R, Monté GC, Sala-Llonch R, Bosch B, Fortea J, Lladó A, Antonell A, Balasa M, Bargalló N, Molinuevo JL.

J Alzheimers Dis. 2016;51(3):827-35. doi: 10.3233/JAD-150899.

PMID:
26923015
13.

Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias.

Morenas-Rodríguez E, Cervera-Carles L, Vilaplana E, Alcolea D, Carmona-Iragui M, Dols-Icardo O, Ribosa-Nogué R, Muñoz-Llahuna L, Sala I, Belén Sánchez-Saudinós M, Blesa R, Clarimón J, Fortea J, Lleó A.

J Alzheimers Dis. 2016;50(2):539-46. doi: 10.3233/JAD-150746.

PMID:
26682689
14.

Assessing the role of TUBA4A gene in frontotemporal degeneration.

Dols-Icardo O, Iborra O, Valdivia J, Pastor P, Ruiz A, de Munain AL, Sánchez-Valle R, Álvarez V, Sánchez-Juan P, Lleó A, Fortea J, Blesa R, Cardona F, Baquero M, Alonso MD, Ortega-Cubero S, Pastor MA, Razquin C, Boada M, Hernández I, Gorostidi A, Moreno F, Zulaika M, Lladó A, Coto E, Combarros O, Pérez-Tur J, Clarimón J; Dementia Genetics Spanish Consortium (DEGESCO)..

Neurobiol Aging. 2016 Feb;38:215.e13-4. doi: 10.1016/j.neurobiolaging.2015.10.030.

PMID:
26675813
15.

Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation.

Carmona-Iragui M, Fernández-Arcos A, Alcolea D, Piazza F, Morenas-Rodriguez E, Antón-Aguirre S, Sala I, Clarimon J, Dols-Icardo O, Camacho V, Sampedro F, Munuera J, Nuñez-Marin F, Lleó A, Fortea J, Gómez-Ansón B, Blesa R.

J Alzheimers Dis. 2016;50(1):1-7. doi: 10.3233/JAD-150614.

PMID:
26639966
16.

The Burden of Moderate-To-Severe Irritable Bowel Syndrome With Constipation (Ibs-C) In France: A Comparison With The European Results From The Ibis-C Observational Study.

Coffin B, Follet M, Mackinnon J, Bertsch J, Fortea J, Tack J.

Value Health. 2015 Nov;18(7):A632. doi: 10.1016/j.jval.2015.09.2237. No abstract available.

17.

Diagnosis And Management of Moderate-To-Severe Irritable Bowel Syndrome With Constipation (Ibs-C) In Germany: Results From The Ibis-C Study.

Layer P, Andresen V, Diemert S, Mackinnon J, Bertsch J, Fortea J, Tack J.

Value Health. 2015 Nov;18(7):A631. doi: 10.1016/j.jval.2015.09.2233. No abstract available.

18.

Economic Burden and Quality of Life of Moderate-To-Severe Irritable Bowel Syndrome With Constipation (Ibs-C) In Germany: Results From The Ibis-C Study.

Layer P, Andresen V, Diemert S, Mackinnon J, Bertsch J, Fortea J, Tack J.

Value Health. 2015 Nov;18(7):A624. doi: 10.1016/j.jval.2015.09.2193. No abstract available.

19.

Patterns of Performance on the Modified Cued Recall Test in Spanish Adults With Down Syndrome With and Without Dementia.

Benejam B, Fortea J, Molina-López R, Videla S.

Am J Intellect Dev Disabil. 2015 Nov;120(6):481-9. doi: 10.1352/1944-7558-120.6.481.

PMID:
26505869
20.

Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study.

Zwan MD, Rinne JO, Hasselbalch SG, Nordberg A, Lleó A, Herukka SK, Soininen H, Law I, Bahl JM, Carter SF, Fortea J, Blesa R, Teunissen CE, Bouwman FH, van Berckel BN, Visser PJ.

Neurology. 2016 Jan 5;86(1):50-8. doi: 10.1212/WNL.0000000000002081.

Items per page

Supplemental Content

Loading ...
Support Center